Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway

References

• Padala SA, Kallam A. Diffuse Large B Cell Lymphoma. 2021 Aug 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Jan–. PMID: 32491728.
   Google Scholar
• Meng X, Min Q, Wang JY. B cell lymphoma. Adv Exp Med Biol. 2020;1254:161–181.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Sukswai N, Lyapichev K, Khoury JD, et al. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020;52(1):53–67.
   PubMed Web of Science ®Google Scholar
• Allen P. Diffuse large B-cell lymphoma in the elderly: current approaches. Curr Oncol Rep. 2020;22(11):114.
   PubMed Web of Science ®Google Scholar
• Coccaro N, Anelli L, Zagaria A, et al. Molecular complexity of diffuse large B-Cell lymphoma: can it be a roadmap for precision medicine? Cancers (Basel). 2020;12(1):185.
   Web of Science ®Google Scholar
• Crombie JL, Armand P. Diffuse large B-Cell lymphoma and high-Grade B-Cell lymphoma: genetic classification and its implications for prognosis and treatment. Hematol Oncol Clin North Am. 2019;33(4):575–585.
   PubMed Web of Science ®Google Scholar
• Kagami Y, Itoh K, Tobinai K, et al. Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan clinical oncology group study, JCOG9508. Int J Hematol. 2012;96(1):74–83.
   PubMed Web of Science ®Google Scholar
• Kubuschok B, Held G, Pfreundschuh M. Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat Res. 2015;165:271–288.
   PubMedGoogle Scholar
• Chiappella A, Castellino A, Vitolo U. State-of-the-art therapy for advanced-stage diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1147–1162.
   PubMed Web of Science ®Google Scholar
• Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol. 2008;142(3):329–347.
   PubMed Web of Science ®Google Scholar
• Vaisheva F, Delbes G, Hales BF, et al. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome. J Androl. 2007;28(4):578–587.
   PubMedGoogle Scholar
• Liu J Quan L, Zhang C, et al. Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. Oncol Lett. 2018;15(3):3321–3328.
   PubMed Web of Science ®Google Scholar
• Wu C, Lyu J, Yang EJ, et al. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun. 2018;9(1):3212.
   PubMedGoogle Scholar
• Gomaa A, Peng D, Chen Z, et al. Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers. Sci Rep. 2019;9(1):16970.
   PubMedGoogle Scholar
• Chien CY, Tsai H-T, Su L-J, et al. Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior. Oncotarget. 2014;5(8):2243–2262.
   PubMedGoogle Scholar
• Zhang W, Xia D, Li Z, et al. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality. Cell Death Dis. 2019;10(8):606.
   PubMedGoogle Scholar
• Jacobsen A, Bosch LJW, Martens-de Kemp SR, et al. Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. Sci Rep. 2018;8(1):7522.
   PubMedGoogle Scholar
• Islam S, Qi W, Morales C, et al. Disruption of aneuploidy and senescence induced by Aurora inhibition promotes intrinsic apoptosis in double hit or double expressor diffuse large B-cell lymphomas. Mol Cancer Ther. 2017;16(10):2083–2093.
   PubMed Web of Science ®Google Scholar
• Kelly KR, Friedberg JW, Park SI, et al. Phase I study of the investigational Aurora a kinase inhibitor alisertib plus rituximab or rituximab/vincristine in relapsed/refractory aggressive B-cell lymphoma. Clin Cancer Res. 2018;24(24):6150–6159.
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560.
   PubMed Web of Science ®Google Scholar
• Zhao CC, Jiao Y, Zhang -Y-Y, et al. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019;10(4):252.
   PubMed Web of Science ®Google Scholar
• Xia Y, Xu-Monette ZY, Tzankov A, et al. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017;31(3):625–636.
   PubMed Web of Science ®Google Scholar
• Hu W, Yang Y, Xi S, et al. Expression of CPEB4 in human glioma and its correlations with prognosis. Medicine (Baltimore). 2015;94(27):e979.
   PubMed Web of Science ®Google Scholar
• Zou J Lei T, Guo P, et al. Mechanisms shaping the role of ERK1/2 in cellular senescence (review). Mol Med Rep. 2019;19(2):759–770.
   PubMed Web of Science ®Google Scholar
• Jain M, Koren S, Miga KH, et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. Nat Biotechnol. 2018;36(4):338–345.
   PubMed Web of Science ®Google Scholar
• Jiang L, Xu Y, Zeng X, et al. Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget. 2015;6(31):31191–31202.
   PubMedGoogle Scholar
• Yahiro K, Satoh M, Nakano M, et al. Low-density lipoprotein receptor-related protein-1 (LRP1) mediates autophagy and apoptosis caused by helicobacter pylori VacA. J Biol Chem. 2012;287(37):31104–31115.
   PubMed Web of Science ®Google Scholar
• Liang Q, Asila A, Deng Y, et al. Osteopontin-induced lncRNA HOTAIR expression is involved in osteoarthritis by regulating cell proliferation. BMC Geriatr. 2021;21(1):57.
   PubMed Web of Science ®Google Scholar
• Soleymani Fard S, Sotoudeh M, Yazdanbod M, et al. Evaluation of the association between androgen receptor and AURKA and its prognostic value in gastric cancer. Int J Hematol Oncol Stem Cell Res. 2019;13(4):174–182.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods. 2001;25(4):402–8.
   PubMed Web of Science ®Google Scholar
• Ji G, Zhou W, Li X, et al. Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster. Mol Med Rep. 2021;23(3). DOI:10.3892/mmr.2021.11826.
   Web of Science ®Google Scholar
• Wen QJ, Yang Q, Goldenson B, et al. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015;21(12):1473–80.
   PubMed Web of Science ®Google Scholar
• Zhu NL, Asahina K, Wang J, et al. Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem. 2012;287(13):10355–10367.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
   PubMed Web of Science ®Google Scholar
• Gobba S, Moccia AA, Gulden-Sala W, et al. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: a large retrospective study from 4 institutions. Hematol Oncol. 2018;36(1):84–92.
   PubMed Web of Science ®Google Scholar
• Hirst J, Godwin AK. AURKA inhibition mimics BRCAness. Aging (Albany NY). 2017;9(9):1945–1946.
   PubMedGoogle Scholar
• Sun X, Liu Q, Huang J, et al. Transcriptome-based stemness indices analysis reveals platinum-based chemo-therapeutic response indicators in advanced-stage serous ovarian cancer. Bioengineered. 2021;12(1):3753–3771.
   PubMed Web of Science ®Google Scholar
• Chen G, Yu M, Cao J, et al. Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis. Bioengineered. 2021;12(1):5149–5161.
   PubMed Web of Science ®Google Scholar
• Stoddart MJ. Cell viability assays: introduction. Methods Mol Biol. 2011;740:1–6.
   PubMedGoogle Scholar
• Yuan X, Gajan A, Chu Q, et al. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018;37(4):733–748.
   PubMed Web of Science ®Google Scholar
• Shang S, Hua F, Hu ZW. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8(20):33972–33989.
   PubMedGoogle Scholar
• Ruiduo C, Ying D, Qiwei W. CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating β-catenin. Biomed Pharmacother. 2018;107:689–695.
   PubMed Web of Science ®Google Scholar
• Jeong WJ, Ro EJ, Choi KY. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. NPJ Precis Oncol. 2018;2(1):5.
   PubMedGoogle Scholar
• Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170(1):17–33.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng M, Chen Q, et al. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. Eur J Pharmacol. 2019;843:145–153.
   PubMed Web of Science ®Google Scholar
• Tian P, Zhu Y, Zhang C, et al. Ras-ERK1/2 signaling contributes to the development of colorectal cancer via regulating H3K9ac. BMC Cancer. 2018;18(1):1286.
   PubMedGoogle Scholar
• Zhao X, Wang X, Li Q, et al. FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway. Cell Death Dis. 2018;9(2):46.
   PubMedGoogle Scholar